Edited by former Washington, D.C. bureau chief David Leonhardt, The Upshot is the latest Times' online editorial offering and is partly aimed at replacing Nate Silver's popular FiveThirtyEight blog.
"You have no shortage of excellent news sources," wrote Leonhardt on the blog Tuesday. "We believe many people don't understand the news as well as they would like."
"We believe we can help readers get to that level of understanding by writing in a direct, plain-spoken way, the same voice we might use when writing an email to a friend. We'll be conversational without being dumbed down," he said.
The launch follows other similar efforts by competitors that are interested in providing sharper analysis and data-embedded stories. Data-centric journalism has become trendy in American newsrooms in recent months as news organizations seek product differentiation through technology and social media. The software applications used to process data and illustrate results in charts, quizzes and maps are cheaper, if not free online. And branded blogs are seen as an efficient means to post stories quickly to dedicated audiences to generate greater web traffic.
Hot Transportation Stocks To Own Right Now: Shenandoah Telecommunications Co(SHEN)
Shenandoah Telecommunications Company, a diversified telecommunications company, provides regulated and unregulated telecommunications services to end-user customers and other communications providers in the southeastern United States. It offers a suite of voice, video, and data communications services; and sells telecommunications equipment. The company?s Wireless segment provides digital wireless service to a portion of a four-state area covering the region from Harrisburg, York, and Altoona, Pennsylvania to Harrisonburg, Virginia. It owns 149 towers and leases tower space to other wireless communications providers in Virginia, West Virginia, Maryland, and Pennsylvania. This segment also offers personal communications services through a digital wireless telephone and data network. Its Wireline segment provides regulated and unregulated telephone services and leases fiber optic facilities primarily in the northern Shenandoah Valley. This segment also offers information s ervices and Internet access to customers in the northern Shenandoah Valley and surrounding areas. In addition, it is involved in the resale of long distance service for calls placed to locations outside the regulated telephone service area by telephone customers. As of December 31, 2011, this segment had approximately 1,410 dial-up customers and 12,351 digital subscriber line customers, as well as served approximately 10,483 long distance customers. The company?s Cable Television segment provides coaxial cable-based television service in the portions of Shenandoah County, Virginia, as well as in communities in West Virginia, southern and southwestern Virginia, and western Maryland. It had approximately 137,238 cable revenue generating units. The company was founded in 1902 and is headquartered in Edinburg, Virginia.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Horizon Pharma (NASDAQ: HZNP) and Pernix Therapeutics Holdings (NASDAQ: PTX). In trading on Wednesday, telecommunications services shares were relative laggards, down on the day by about 0.39 percent. Top decliners in the sector included Shenandoah Telecommunications Co (NASDAQ: SHEN), off 3.3 percent, and CalAmp (NASDAQ: CAMP), down around 2.4 percent.
Top 10 Tech Companies To Own In Right Now: Prosensa Holding NV (RNA)
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.
Advisors' Opinion:- [By Brian Orelli]
Ironically, phase 3 data from Sarepta's direct competitor -- GlaxoSmithKline (NYSE: GSK ) and Prosensa's (NASDAQ: RNA ) drisapersen -- that's due in the fourth quarter could help the FDA answer the question about whether dystrophin is an acceptable surrogate endpoint. If increases in dystrophin correlate with clinical outcomes, it would support approving eteplirsen with less data. It's not clear to me whether Glaxo and Prosensa would have to share that correlation with the FDA -- the clinical phase 3 data should be sufficient for approval -- and if it does make those calculations whether the FDA could legally use it to support the approval of another drug since NDA data is proprietary while under patent.
- [By John Udovich]
Recent news surrounding small cap biotech stocks like�Xencor Inc (NASDAQ: XNCR), Prosensa Holding NV (NASDAQ: RNA),�Puma Biotechnology Inc (NYSE: PBYI),�Geron Corporation (NASDAQ: GERN)
and TNI BioTech Inc (OTCQB: TNIB) show that while the sector and appetite for biotech�IPOs may have cooled, lottery tickets can still be found or occur in the sector. Just consider the following recent news or trends: - [By Keith Speights]
An "alley-oop" from the opponent
Prosensa (NASDAQ: RNA ) shares made something of a slam dunk this week, jumping more than 16%. That dunk was made with what amounts to an "alley-oop" from its primary rival, Sarepta Therapeutics (NASDAQ: SRPT ) . - [By Sean Williams]
Shares of Sarepta climbed to a 52-week high of $55.61 in September shortly after an experimental rival drug, drisapersen, developed by Prosensa (NASDAQ: RNA ) and GlaxoSmithKline (NYSE: GSK ) , missed its primary end point by a mile in late-stage trials. However, Sarepta also tanked just weeks later after the Food and Drug Administration decided against supporting an accelerated drug approval for eteplirsen; the agency would not make the connection that increased dystrophin production led to its remarkable trial results.�Also, given the recent failure of drisapersen in a phase 3 study, the FDA felt it pertinent that Sarepta engage in a broader study. Shares ultimately dipped as low as $12.12.�
Top 10 Tech Companies To Own In Right Now: Xilinx Inc (XLNX)
Xilinx, Inc. (Xilinx), incorporated on February 5, 1984, designs, develops and markets programmable platforms. These programmable platforms have a number of components, including integrated circuits (ICs) in the form of programmable logic devices (PLDs), including Extensible Processing Platforms (EPPs); software design tools to program the PLDs; targeted reference designs; printed circuit boards, and intellectual property (IP), which consists of Xilinx and various third-party verification and IP cores. In addition to its programmable platforms, Xilinx provides design services, customer training, field engineering and technical support. The Company�� PLDs include field programmable gate arrays (FPGAs), complex programmable logic devices (CPLDs) that its customers program to perform logic functions, and EPPs. Xilinx�� products are offered to electronic equipment manufacturers in end markets, such as wired and wireless communications, industrial, scientific and medical, aerospace and defense, audio, video and broadcast, consumer, automotive and data processing. The Company sells its products globally through independent domestic and foreign distributors and through direct sales to original equipment manufacturers (OEMs) by a network of independent sales representative firms and by a direct sales management organization. In January 2011, the Company acquired AutoESL Design Technologies, Inc. In August 2012, the Company acquired embedded Linux solutions provider PetaLogix.
Product Families
The 7 series devices that comprise the Company�� 28-nanometer (nm) product families are fabricated on a high-K metal gate 28-nm process technology. These devices are based on an architecture, which enables design and IP portability and re-use across all families, as well as provides designers the ability to achieve the appropriate combination of I/O support, performance, feature quantities, packaging and power consumption to address a range of applications. The 7 series devices consist of! three families: Virtex-7 FPGA, Kintex-7 FPGAs and Artix-7 FPGAs. The Zynq-7000 family is the family of Xilinx EPPs. The Virtex-6 FPGA family consists of 13 devices and is the sixth generation in the Virtex series of FPGAs.
Virtex-6 FPGAs are fabricated on a high-performance, 40-nm process technology. There are three Virtex-6 families: Virtex-6 LXT FPGAs, Virtex-6 SXT FPGAs and Virtex-6 HXT FPGAs. The Spartan-6 family is the PLD industry�� 45-nm high-volume FPGA family, consisting of 11 devices in two product families: Spartan-6 LX FPGAs and Spartan-6 LXT FPGAs. The Virtex-5 FPGA family consists of 26 devices in five product families: Virtex-5 LX FPGAs for logic-intensive designs, Virtex-5 LXT FPGAs for high-performance logic with serial connectivity, Virtex-5 SXT FPGAs for high-performance DSP with serial connectivity, Virtex-5 FXT FPGAs for embedded processing with serial connectivity and Virtex-5 TXT FPGAs for high-bandwidth serial connectivity. Prior generation Virtex families include Virtex-4, Virtex-II Pro, Virtex-II, Virtex-E and the original Virtex family. Spartan family FPGAs include 90-nm Spartan-3 FPGAs, the Spartan-3E family and the Spartan-3A family. Prior generation Spartan families include Spartan-IIE, Spartan-II, Spartan XL and the original Spartan family.
Design Platforms and Services
The Company offers three types of programmable platforms. The Base Platform is the delivery vehicle for all of its new silicon offerings used to develop and run customer-specific software applications and hardware designs. The Base Platform consists of FPGA silicon; Integrated Software Environment (ISE) Design Suite design environment; integration support of optional third-party synthesis, simulation, and signal integrity tools; reference designs; development boards and IP. The Domain-Specific Platform targets one of the three primary Xilinx FPGA user profiles: the embedded processing developer; the DSP developer; or the logic/connectivity developer. The Market-S! pecific P! latform enables software or hardware developers to build and run their specific application or solution. Built for specific markets, such as automotive, consumer, aerospace and defense, communications, audio, video and broadcast, industrial, or scientific and medical, the Market-Specific Platform integrates both the Base and Domain-Specific Platforms.
During April 2012, Xilinx introduced the Vivado Design Suite. Vivado supports Xilinx 7 series FPGAs and Zynq EPPs. Xilinx and various third parties offer hundreds of no charge and fee-bearing IP core licenses covering Ethernet, memory controllers Interlaken and PCIe interface, as well as domain-specific IP in the areas of embedded, DSP and connectivity, and market-specific IP cores. The Company also offers development kits, including hardware, design tools, IP and reference designs. Xilinx offers a range of configuration products, including one-time programmable and in-system programmable storage devices to configure Xilinx FPGAs. These programmable read-only memory (PROM) products support all of the Company�� FPGA devices. Xilinx and certain third parties have developed and offer a ecosystem of IP, boards, tools, services and support through the Xilinx alliance program. Xilinx also works with these third parties to promote its programmable platforms through third-party tools, IP, software, boards and design services. Xilinx engineering services provide customers with engineering, ranging from hands-on training to full design creation and implementation.
The Company competes with Altera Corporation, Lattice Semiconductor Corporation and Microsemi Corporation.
Advisors' Opinion:- [By Riddhi Kharkia] rd and maintain its streak of impressive performances.
Beating competition
Altera's performance in the recently reported first quarter was much better than Xilinx. Its revenue grew 12% year-over-year to $461 million, comprehensively ahead of the $438 million consensus target. Earnings, meanwhile, came in at $0.37 per share, while analysts were looking for $0.32.
Altera's outlook was also strong. The company expects revenue in the range of $470 million-$488 million in the ongoing quarter, blowing past the $461 million estimate. In comparison, rival Xilinx's performance left a lot to be desired. The company's earnings missed estimates, and its revenue outlook for the current quarter also lagged expectations, as it saw a drop in orders from a couple of large communication customers.
Hence, Altera seems to be executing better than Xilinx. Going forward, considering Altera's product development efforts, there's a strong chance that it will be able to overtake Xilinx in the programmable logic devices market.
Fresh products
Altera's new products now account for almost half of its total revenue. The 28-nanometer process has been the primary driver for Altera so far, and the company seems to have successfully taken away some market share from Xilinx in this area. While Xilinx cited delays in LTE deployment as the reason behind its sluggish performance in the previous quarter, Altera was singing a different tune.
In fact, the roll out of LTE by China Mobile (CHL) resulted in 20% sequential growth in Altera's wireless business. In addition, Altera is also counting on the growing adoption of 3G in India and other developing countries to propel its business higher.
The company's focus on making its production processes more efficient has helped it land some solid design wins. Altera has already started sampling its 20-nanometer process with customers, extending its chip portfolio further. However, it is the 14-nanometer Fin
Top 10 Tech Companies To Own In Right Now: China Sunergy Co. Ltd.(CSUN)
China Sunergy Co., Ltd. designs, develops, manufactures, and sells solar cells and solar modules. It offers monocrystalline and multicrystalline silicon solar cells; and standard P-type solar cells and HP solar cells, as well as emitter cells. The company sells its products to module manufacturers, system integrators, and distributors. It sells solar cells and modules under CSUN and CEEG brand names primarily in Europe, the People?s Republic of China, India, South Korea, Australia, and the Untied States. The company was founded in 2004 and is headquartered in Nanjing, the People?s Republic of China.
Advisors' Opinion:- [By Eric Volkman]
China Sunergy (NASDAQ: CSUN ) results for the company's fiscal Q4 and 2012 have been released. For the quarter, total sales were $54.4 million, less than half the $110.8 million the firm posted in the same period the previous year. Net loss, meanwhile, was steeper at $70.5 million ($5.27 per diluted American Depositary Share), compared to Q4 2011's red figure of $49.6 million ($3.71).
Top 10 Tech Companies To Own In Right Now: TigerLogic Corporation(TIGR)
TigerLogic Corporation engages in the design, development, sale, and support of software infrastructure, Internet search enhancement tools, and a social media content aggregation platform in North America, the United Kingdom, France, and Germany. The company offers Yolink, a search enhancement technology; and TigerLogic XDMS, an enterprise native XML database management server with data and document centric capabilities. It also provides multi-dimensional databases consisting of D3 data base management system that runs on various operating systems and allows application programmers to create new business solution software; mvEnterprise and mvBase, the multi-dimensional database solutions; and TigerLogic dashboard, which allows Pick UDM developers to create Web-based graphical displays of multi-value data. In addition, the company offers rapid application development tools that support the full life cycle of software application development and are used for rapid prototypin g, development, and deployment of graphical user interface client/server and Web applications. Further, it provides Postano, a real-time social media content aggregation platform, which allows users to collect content from various social media sources and display that content on Web pages hosted by the company or others. Additionally, the company offers technical support, consulting, continuing maintenance, customer support, professional, and training services. It serves independent software vendors and software developers, and corporate information technology departments. TigerLogic Corporation sells its products through OEMs, system integrators, specialized vertical application software developers, and consulting organizations, as well as directly to end user organizations and through its Web sites. The company was formerly known as Raining Data Corporation and changed its name to TigerLogic Corporation in April 2008. TigerLogic Corporation was founded in 1987 and is based in Irvine, California.
Advisors' Opinion:- [By Monica Gerson]
TigerLogic (NASDAQ: TIGR) is estimated to post its Q4 earnings.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
Top 10 Tech Companies To Own In Right Now: TeliaSonera AB (TLSN)
TeliaSonera AB is a Sweden-based company engaged in the provision of network access and telecommunication services to individual and business customers. The Company is organized into four business segments: the Mobile Services segment provides mobile services, which include mobile voice and data, mobile content, Wireless Local Area Network (WLAN) Hotspots, mobile broadband and Wireless Office to the consumer and enterprise markets; the Broadband Services segment provides services for connecting homes and offices, including broadband over copper, fiber and cable, television (TV), voice over Internet, home communications services, Internet Protocol- Virtual Private Network (IP-VPN)/Business Internet, leased lines and traditional telephony; the Eurasia segment comprises mobile operations in Kazakhstan, Azerbaijan, Uzbekistan, Tajikistan, Georgia, Moldova and Nepal, and the Other operations segment comprises Other Business Services, TeliaSonera Holding and Corporate functions. Advisors' Opinion:- [By Sarah Jones]
TeliaSonera AB (TLSN) lost 2.1 percent to 42.47 kronor after Sweden�� biggest phone company reported first-quarter net income of 4.11 billion kronor ($629 million), little changed from a year earlier. Analysts had predicted 4.32 billion kronor of profit, according to the average of 15 estimates compiled by Bloomberg. Sales fell 4.4 percent.
- [By Jonathan Morgan]
TeliaSonera (TLSN) slid 1.9 percent to 47.56 Swedish kronor. Solidium Oy, Finland�� equity-asset manager, sold 1.6 percent of shares in the Stockholm-based company in an accelerated book building to institutional investors, it said in a statement.
Top 10 Tech Companies To Own In Right Now: Senesco Technologies Inc (SNTI)
Senesco Technologies, Inc., incorporated on September 30. 1999, is engaged in utilize its eukaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for human therapeutic applications to develop approaches to treat cancer and inflammatory diseases. In agricultural applications, the Company has licensed applications of the Factor 5A, DHS and Lipase platforms to develop the productivity of fruits, flowers, vegetables, agronomic and biofuel feedstock crops through the control of cell death and growth in plants.
Human Therapeutic Applications
The Company has developed a therapeutic candidate, SNS01-T, an improved formulation of SNS01, for the potential treatment of multiple myeloma and non-Hodgkin B-cell lymplomas. SNS01-T utilizes the Company's Factor 5A technology and consists of two components, which include a DNA plasmid (pDNA), expressing human eIF5A containing a lysine to arginine substitution at amino acid position 50, (eIF5AK50R), and a small inhibitory RNA (siRNA). These two components are combined in a fixed ratio with a polymer, polyethyleneimine (PEI), which enables self-assembly of the DNA and RNA into nanoparticles with demonstrated enhanced delivery to tissues and protection from degradation in the blood stream. The Company has also demonstrated that the combination of lenalidomide and SNS 01-T performs better than either treatment alone in mouses xenograft models of human mantle cell lymphoma. The Company's human therapeutic research program, which consists of pre-clinical in-vitro and in-vivo experiments designed to assess the role and mode of action of Factor 5A in human diseases and a phase 1a/2b clinical trial.
The Company competes with Celgene, Inc., Takeda/Millennium, ONYX Pharmaceuticals, Inc., Amgen Inc., Janssen Biotech, Inc., Novartis AG, and Pharmacyclics, Inc.
Agricultural Applications
The Company's agricultural research focuses on the discovery and develo! pment of certain gene technologies, which are designed to confer positive traits on fruits, flowers, vegetables, forestry species and agronomic crops. The Company's research and development initiatives for agriculture include develop and implement the DHS and Factor 5A gene technology in banana, canola, cotton, turfgrass, rice, alfalfa, corn, soybean and trees; and test the resultant crops for new beneficial traits such as increased yield, increased tolerance to environmental stress, disease resistance and more efficient use of fertilizer.
The Company competes with Mendel Biotechnology, Renessen LLC, Exelixis Plant Sciences, Inc., and Syngenta International AG.
Advisors' Opinion:- [By CRWE]
Today, SNTI has shed (-2.44%) down -0.0010 at $.0400 with�723,673 shares in play thus far (ref. google finance Delayed: 2:58PM EDT October 7, 2013).
Senesco Technologies, Inc. previously reported it has entered into a securities purchase agreement with certain investors to raise $1.725 million in gross proceeds through the sale of 69,000,000 shares of its common stock. The common stock was priced at $0.025 per share.
The offering is expected to close on or about October 2, 2013, subject to customary closing conditions. The net proceeds of the financing will be used primarily for working capital, research and development and general corporate purposes.
No comments:
Post a Comment